Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab after diabetic lumbar spine fusion
ChiCTR2100051607Phase 4Not yet recruiting
- Sponsor
- Shenzhen People's Hospital
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of denosumab in osteoporosis, lumbar spinal stenosis (LSS), Herniated Lumbar Disk and 1 more (2 arms), sponsored by Shenzhen People's Hospital. Primary endpoints: osteocalcin in the N terminal molecular fragment, n-terminal propeptide P1NP of procollagen type 1 and 16 more. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
denosumab
03
Conditions
osteoporosislumbar spinal stenosis (LSS)Herniated Lumbar Disktype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100051607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051607.